Mosapride (citrate dihydrate)

Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo[2].

Product Specifications

CAS Number

[636582-62-2]

Product Name Alternative

TAK-370 (citrate dihydrate) ; AS-4370 (citrate dihydrate)

UNSPSC

12352005

Hazard Statement

H318

Target

5-HT Receptor; Cytochrome P450; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/mosapride-citrate-dihydrate.html

Purity

99.87

Solubility

10 mM in DMSO

Smiles

O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC.O=C(CC(C(O)=O)(O)CC(O)=O)O.O.O

Molecular Formula

C27H37ClFN3O12

Molecular Weight

650.05

Precautions

H318

References & Citations

[1]Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013;386 (10) :905-16.|[2]Mine Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. The Journal of pharmacology and experimental therapeutics. 1997;283 (3) :1000-8.